Compare the efficacy and safty of once and twice daily timolol eye drope in treatment of glaucoma

Study of the Efficacy and safty of Once and Twice daily timolol(0.5% solution) treatment in controlling intraocular pressure at Menelik || comprehensive specialized hospital, Addis Ababa,Ethiopia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202412559535575

Enrollment

Registered

2024-12-09

Start date

2022-07-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Timolol Once Daily

Twice daily Group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: New patients diagnosed with early open angle glaucoma whose intraocular pressure is lower than 35 Patients who discontinued their anti-glaucoma medication for more than 6 weeks

Exclusion criteria

Exclusion criteria: Patients diagnosed with angle closure glaucoma Patients already taking glaucoma medications Intraocular pressure greater than 35 Patients with moderate and advanced glaucoma (VCDR>0.65) Patients who had any intraocular surgery e.g trabeculectomy, cataract surgery. .etc Patients on systemic medications which could affect intraocular pressure Additional ocular conditions like uveitis, trauma

Design outcomes

Primary

Measure	Time frame
Intraocular pressure	—

Secondary

Measure	Time frame
Side effects of treatment	—

Countries

Ethiopia

Contacts

Public ContactMuhidin Kergeda

Ophthalmologist

barcho7@gmail.com0912637992

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026